Cosentyx and Skin hyperpigmentation - a phase IV clinical study of FDA data
Skin hyperpigmentation is found among people who take Cosentyx, especially for people who are female, 50-59 old, have been taking the drug for 1 - 6 months.
The phase IV clinical study analyzes which people take Cosentyx and have Skin hyperpigmentation. It is created by eHealthMe based on reports of 170,593 people who have side effects when taking Cosentyx from the FDA, and is updated regularly. You can use the study as a second opinion to make health care decisions.
Phase IV trials are used to detect adverse drug outcomes and monitor drug effectiveness in the real world. With medical big data and AI algorithms, eHealthMe is running millions of phase IV trials and makes the results available to the public. Our original studies have been referenced on 600+ medical publications including The Lancet, Mayo Clinic Proceedings, and Nature.
170,593 people reported to have side effects when taking Cosentyx.
Among them, 54 people (0.03%) have Skin hyperpigmentation.
What is Cosentyx?
Cosentyx has active ingredients of secukinumab. It is often used in psoriatic arthritis. eHealthMe is studying from 141,651 Cosentyx users for its effectiveness, alternative drugs and more.
What is Skin hyperpigmentation?
Skin hyperpigmentation (disorders affect the colour of your skin) is found to be associated with 1,460 drugs and 810 conditions by eHealthMe.
Number of Cosentyx and Skin hyperpigmentation reports submitted per year:
Time on Cosentyx when people have Skin hyperpigmentation *:
- < 1 month: 33.33 %
- 1 - 6 months: 66.67 %
- 6 - 12 months: 0.0 %
- 1 - 2 years: 0.0 %
- 2 - 5 years: 0.0 %
- 5 - 10 years: 0.0 %
- 10+ years: 0.0 %
Gender of people who have Skin hyperpigmentation when taking Cosentyx *:
- female: 58 %
- male: 42 %
Age of people who have Skin hyperpigmentation when taking Cosentyx *:
- 0-1: 0.0 %
- 2-9: 0.0 %
- 10-19: 0.0 %
- 20-29: 11.54 %
- 30-39: 26.92 %
- 40-49: 11.54 %
- 50-59: 38.46 %
- 60+: 11.54 %
Common drugs people take besides Cosentyx *:
- Zolpidem: 5 people, 9.26%
- Humira: 5 people, 9.26%
- Triamcinolone: 4 people, 7.41%
- Methotrexate: 3 people, 5.56%
- Lamisil: 3 people, 5.56%
- Calcipotriene And Betamethasone Dipropionate: 2 people, 3.70%
- Cardizem: 2 people, 3.70%
- Hydrocortisone: 2 people, 3.70%
- Ibuprofen: 2 people, 3.70%
- Magnesium: 2 people, 3.70%
Common side effects people have besides Skin hyperpigmentation *:
- Psoriasis (immune-mediated disease that affects the skin): 25 people, 46.30%
- Rashes (redness): 20 people, 37.04%
- Itching: 14 people, 25.93%
- Joint Pain: 12 people, 22.22%
- Skin Exfoliation (removal of the oldest dead skin cells): 11 people, 20.37%
- Drug Ineffective: 10 people, 18.52%
- Dry Skin: 9 people, 16.67%
- Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 8 people, 14.81%
- Scab (a hard coating on the skin formed during the wound healing): 7 people, 12.96%
- Stress And Anxiety: 7 people, 12.96%
Common conditions people have *:
- Psoriasis (immune-mediated disease that affects the skin): 38 people, 70.37%
- Psoriatic Arthropathy (inflammation of the skin and joints with kin condition which typically causes patches (plaques) of red, scaly skin to develop): 10 people, 18.52%
- Sleep Disorder: 5 people, 9.26%
- High Blood Pressure: 3 people, 5.56%
- High Blood Cholesterol: 3 people, 5.56%
- Hidradenitis (chronic disease of a type of sweat gland): 2 people, 3.70%
- Erythema Nodosum (skin inflammation that results in reddish, painful, tender lumps most commonly located in the front of the legs below): 2 people, 3.70%
- Arrhythmias (irregular heartbeat): 2 people, 3.70%
- Nail Psoriasis (a nail disease, nail bed separation, and discoloration): 1 person, 1.85%
- Insomnia (sleeplessness): 1 person, 1.85%
* Approximation only. Some reports may have incomplete information.
Do you take Cosentyx and have Skin hyperpigmentation?Check whether Skin hyperpigmentation is associated with a drug or a condition
How to use the study?
You can discuss the study with your doctor, to ensure that all drug risks and benefits are fully discussed and understood.
How severe was Skin hyperpigmentation and when was it recovered:
Expand to all the drugs that have ingredients of secukinumab:
Alternative drugs to, pros and cons of Cosentyx:
- Cosentyx (141,651 reports)
Common Cosentyx side effects:
- Drug ineffective: 24,399 reports
- Psoriasis (immune-mediated disease that affects the skin): 21,919 reports
- Pain: 14,000 reports
- Joint pain: 12,306 reports
- Rashes (redness): 9,379 reports
- Malaise (a feeling of general discomfort or uneasiness): 7,934 reports
- Fatigue (feeling of tiredness): 7,884 reports
- Itching: 7,536 reports
Browse all side effects of Cosentyx:a b c d e f g h i j k l m n o p q r s t u v w x y z
Skin hyperpigmentation treatments and more:
- Skin hyperpigmentation (10,564 reports)
COVID vaccines that are related to Skin hyperpigmentation:
- Skin hyperpigmentation in Moderna COVID Vaccine
- Skin hyperpigmentation in Pfizer BioNTech Covid Vaccine
- Skin hyperpigmentation in Johnson and Johnson Covid Vaccine
Common drugs associated with Skin hyperpigmentation:
- Adapalene: 2,682 reports
- Magnevist: 497 reports
- Latisse: 426 reports
- Prednisone: 406 reports
- Omniscan: 371 reports
- Aspirin: 307 reports
- Optimark: 300 reports
- Renagel: 271 reports
- Multihance: 244 reports
- Ortho evra: 232 reports
All the drugs that are associated with Skin hyperpigmentation:
- Skin hyperpigmentation (1,460 drugs)
Common conditions associated with Skin hyperpigmentation:
- Acne: 1,803 reports
- Birth control: 296 reports
- High blood pressure: 188 reports
- Multiple myeloma: 155 reports
- Pain: 126 reports
All the conditions that are associated with Skin hyperpigmentation:
- Skin hyperpigmentation (810 conditions)
How the study uses the data?
The study uses data from the FDA. It is based on secukinumab (the active ingredients of Cosentyx) and Cosentyx (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 600+ medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Advair Diskus 100/50 and Drug Ineffective - 13 seconds ago
- Lupron Depot and Wound Infection - 23 seconds ago
- Ankylosing Spondylitis and Sinusitis - 23 seconds ago
- Ankylosing Spondylitis and Sinusitis - Acute - 23 seconds ago
- Nasarel and Atrovent drug interaction - 28 seconds ago
- Yaz and Etodolac drug interaction - 28 seconds ago
- Blood Cholesterol Decreased and drugs of ingredients of aspirin - 38 seconds ago
- Terbutaline Sulfate and Cough - 43 seconds ago
- Omnaris vs. Fluticasone Propionate - 45 seconds ago
- Terbutaline Sulfate and Drug Ineffective - 45 seconds ago